Skip to content

Net debt / EBITDA at other companies

Gilead Sciences logo
Gilead SciencesGILD
1.4×-0.6×
Arrowhead Research logo
Arrowhead ResearchARWR
-0.3×
Alkermes logo
AlkermesALKS
5.3×+4.7×
TG Therapeutics logo
TG TherapeuticsTGTX
2.1×+0.1×
Roivant Sciences logo
Roivant SciencesROIV
-0×
ALN
Alnylam PharmaceuticalsALNY
-1.8×

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Calculated from Mirum Pharmaceuticals, Inc.’s reported figures.

net debt/ebitda=-116.1×

Based on the most recent quarter.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s net debt / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s net debt / EBITDA?
Mirum Pharmaceuticals, Inc. (MIRM) reported net debt / EBITDA of -116.1× in Q4 2025.
What does net debt / EBITDA mean?
Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.